Chemotherapy News and Research

Latest Chemotherapy News and Research

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Genta announces private placement of Convertible Notes for $25M

Genta Incorporated announced today that the Company has entered into definitive agreements with institutional investors for a private placement of Convertible Notes totaling $25 million in gross proceeds. The transaction is expected to close on or about March 10, 2010, subject to the satisfaction of customary closing conditions.

8 Mar 2010

Improvements needed in communicating cancer recurrence risks and treatment decisions with patients

A new study has found that one in three early-stage breast cancer patients who received genomic testing when deciding about treatment options felt they did not fully understand their discussions with physicians about their test results and their risk of recurrence. About one in four experienced distress when receiving their test results.

8 Mar 2010

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

Breast cancer patients with early stage disease that has spread to only one lymph node may not benefit from radiation after mastectomy, because of the low present-day risk of recurrence following modern surgery and systemic therapy, a finding that could one day change the course of treatment for thousands of women diagnosed each year, according to researchers at The University of Texas M. D. Anderson Cancer.

7 Mar 2010

Health reform fact check: Republicans have used reconciliation, Obama bill will bring down health costs

Several news organization have "fact checks" on the reconciliation procedure and health reform provisions.

6 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

New anti-tumour vaccine for mesothelioma shows promising results

A vaccine against mesothelioma, a cancer associated with exposure to asbestos, has shown early promise in its first clinical trial.

5 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

Combating liver fluke: Queen's University Belfast heads international research effort

Queen's University Belfast is spearheading a £1 million international research effort to combat liver fluke - a parasite which causes disease in livestock, resulting in billions of pounds in losses every year to farmers around the world.

5 Mar 2010

St. Baldrick’s Foundation Infusion Center opened for children undergoing chemotherapy treatments

The Children’s Center for Cancer and Blood Diseases of Las Vegas, Nevada’s first and only official nonprofit pediatric cancer center, is proud to announce the opening of an infusion center on March 4. The new St. Baldrick’s Foundation Infusion Center will specialize in intravenous (IV) treatments for children currently undergoing chemotherapy treatments.

5 Mar 2010

Second AACR cancer research conference to be hosted in Dead Sea, Jordan

The second American Association for Cancer Research Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic provides attendees with an overview of the most advanced cancer research in a variety of fields, including the tumor microenvironment, microRNAs, signal transduction and novel therapeutic development.

5 Mar 2010

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Kyto Biopharma Inc., is pleased to announce that it has signed a licensing agreement with the Research Foundation of the State University of New York. The licensing agreement grants Kyto patent rights to the Transcobalamin (Vitamin B12) Receptor and to an additional broad group of other patents which are critical to Kyto’s research and development strategy for the treatment of cancer.

5 Mar 2010

SpePharm Holding acquires global rights to Savene from TopoTarget

SpePharm Holding, BV today announced the acquisition of the worldwide (with the exception of North and South America) rights to Savene® from TopoTarget A/S (Copenhagen, Denmark). As part of the acquisition SpePharm will also take on the European sales force of TopoTarget. Savene®, which has been marketed by TopoTarget since its approval by the EMEA in July 2006, is the only approved product for the treatment of extravasations, or leakage out of the blood stream, of certain commonly used anticancer drugs known as anthracyclines.

4 Mar 2010

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Cell Therapeutics, Inc. announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

4 Mar 2010

Recurrence of breast cancer in older women: Delaying post-surgical radiation treatment increases risk

Older women who have had breast cancer surgery have a greater risk of the cancer returning if they delay their post-surgical radiation treatment, report Dana-Farber Cancer Institute scientists.

4 Mar 2010

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

4 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

Seattle Genetics generates $110M through ADC technology license agreements

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech, Inc., a wholly owned member of the Roche Group.

3 Mar 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Genta announces private placement of Convertible Notes for $25M

Improvements needed in communicating cancer recurrence risks and treatment decisions with patients

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

Health reform fact check: Republicans have used reconciliation, Obama bill will bring down health costs

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

New anti-tumour vaccine for mesothelioma shows promising results

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Combating liver fluke: Queen's University Belfast heads international research effort

St. Baldrick’s Foundation Infusion Center opened for children undergoing chemotherapy treatments

Second AACR cancer research conference to be hosted in Dead Sea, Jordan

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

SpePharm Holding acquires global rights to Savene from TopoTarget

TNFerade's suppression of cancer metastases: Mechanisms revealed

Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue

Recurrence of breast cancer in older women: Delaying post-surgical radiation treatment increases risk

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Seattle Genetics generates $110M through ADC technology license agreements

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in